Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTXNASDAQ:DYAINASDAQ:PMCBNASDAQ:RNXT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.44+5.1%$1.16$0.85▼$4.40$38.29M0.5732,859 shs27,826 shsDYAIDyadic International$1.22-0.8%$1.32$0.93▼$2.67$36.71M0.9869,761 shs33,563 shsPMCBPharmaCyte Biotech$1.24$1.43$1.03▼$2.42$8.51M-0.5321,568 shs2,797 shsRNXTRenovoRx$0.96-1.0%$0.95$0.75▼$1.69$35.09M1.1275,543 shs71,067 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics-2.14%+0.74%+7.87%+1.81%+7.04%DYAIDyadic International+3.39%+0.83%-10.95%-17.01%-12.24%PMCBPharmaCyte Biotech-3.88%+8.30%-6.06%-23.27%-41.51%RNXTRenovoRx-0.23%+2.08%-3.02%-28.69%-19.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTXAkari TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ADYAIDyadic International2.879 of 5 stars3.55.00.00.03.01.70.0PMCBPharmaCyte Biotech1.6261 of 5 stars0.03.00.00.03.30.81.9RNXTRenovoRx2.1662 of 5 stars3.53.00.00.02.41.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 0.00N/AN/AN/ADYAIDyadic International 3.00Buy$6.00391.80% UpsidePMCBPharmaCyte Biotech 0.00N/AN/AN/ARNXTRenovoRx 3.00Buy$7.00629.17% UpsideCurrent Analyst Ratings BreakdownLatest PMCB, RNXT, DYAI, and AKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025RNXTRenovoRxAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $11.004/4/2025RNXTRenovoRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.003/27/2025RNXTRenovoRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.00(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A($0.03) per shareN/ADYAIDyadic International$3.50M10.50N/AN/A$0.20 per share6.10PMCBPharmaCyte BiotechN/AN/AN/AN/A$3.27 per shareN/ARNXTRenovoRx$43K815.93N/AN/A($0.28) per share-3.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$10.01MN/A0.00∞N/AN/AN/AN/A5/15/2025 (Estimated)DYAIDyadic International-$6.80M-$0.20N/AN/AN/A-188.09%-149.16%-59.81%5/13/2025 (Estimated)PMCBPharmaCyte Biotech$330K$0.742.34∞N/AN/A0.76%0.45%N/ARNXTRenovoRx-$10.23M-$0.39N/AN/AN/AN/A-205.96%-110.01%5/9/2025 (Estimated)Latest PMCB, RNXT, DYAI, and AKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025RNXTRenovoRx-$0.10N/AN/AN/A$0.23 millionN/A3/31/2025Q4 2024RNXTRenovoRx-$0.12-$0.13-$0.01-$0.12$0.17 million$0.04 million3/26/2025Q4 2024DYAIDyadic International-$0.04-$0.05-$0.01-$0.05$1.60 million$0.82 million3/17/2025Q3 2025PMCBPharmaCyte BiotechN/A-$0.10N/A-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/ADYAIDyadic InternationalN/AN/AN/AN/AN/APMCBPharmaCyte BiotechN/AN/AN/AN/AN/ARNXTRenovoRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.290.29DYAIDyadic International1.545.155.15PMCBPharmaCyte BiotechN/A4.474.47RNXTRenovoRxN/A5.665.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%DYAIDyadic International27.95%PMCBPharmaCyte Biotech34.24%RNXTRenovoRx3.10%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics38.90%DYAIDyadic International28.80%PMCBPharmaCyte Biotech10.20%RNXTRenovoRx7.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics926.59 million16.25 millionNot OptionableDYAIDyadic International730.09 million21.07 millionOptionablePMCBPharmaCyte Biotech46.86 million6.90 millionOptionableRNXTRenovoRx636.55 million22.30 millionNot OptionablePMCB, RNXT, DYAI, and AKTX HeadlinesRecent News About These CompaniesJohns Hopkins Medicine lance le recrutement de patients pour l'essai clinique de phase III TIGeR-PaC en cours de RenovoRxApril 30 at 4:17 PM | zonebourse.comRenovoRx (NASDAQ:RNXT) Given New $11.00 Price Target at Ascendiant Capital MarketsApril 30 at 2:01 AM | americanbankingnews.comJohns Hopkins Medicine lance le recrutement de patients pour l'essai clinique de phase III en cours de Renovorx sur le Tiger-PacApril 29 at 10:28 AM | zonebourse.comJohns Hopkins rejoint l’essai TIGeR-PaC de RenovoRx sur le cancer du pancréasApril 29 at 10:28 AM | fr.investing.comJohns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical TrialApril 29 at 10:28 AM | finance.yahoo.comRenovoRx ramps up production of FDA-cleared RenovoCathApril 18, 2025 | uk.investing.comRamtin Agah Purchases 15,000 Shares of RenovoRx, Inc. (NASDAQ:RNXT) StockApril 18, 2025 | insidertrades.comLe directeur médical de RenovoRx, Agah Ramtin, achète des actions pour 13.500$April 18, 2025 | fr.investing.comLe directeur médical de RenovoRx, Agah Ramtin, achète des actions ordinaires pour 13.500€April 18, 2025 | fr.investing.comRenovorx augmente sa production américaine de dispositifs Renovocath pour répondre à la demande croissante de la communauté oncologiqueApril 16, 2025 | zonebourse.comLe PDG de RenovoRx, Shaun Bagai, acquiert des actions ordinaires pour 6.821$April 16, 2025 | fr.investing.comRenovoRx augmente la production de son dispositif RenovoCath approuvé par la FDAApril 16, 2025 | fr.investing.comRenovo Gains on Bringing Forward RenovoCathApril 16, 2025 | baystreet.caRenovoRx, Inc. (NASDAQ:RNXT) Insider Acquires $16,000.00 in StockApril 15, 2025 | insidertrades.comLe directeur médical de RenovoRx, Ramtin Agah, achète des actions pour 16.000$April 14, 2025 | fr.investing.comRenovoRx, Inc. (NASDAQ:RNXT) Director Laurence Marton Purchases 12,050 SharesApril 11, 2025 | insidertrades.comRenovoRx, Inc. (NASDAQ:RNXT) Insider Buys $21,840.00 in StockApril 10, 2025 | insidertrades.comLe directeur médical de Renovorx, Agah Ramtin, achète des actions pour 21.840$April 9, 2025 | fr.investing.comLe PDG de RenovoRx, Shaun Bagai, achète pour 8.300$ d’actions de la sociétéApril 8, 2025 | fr.investing.comL’action RenovoRx atteint son plus bas niveau sur 52 semaines à 0,77$April 8, 2025 | fr.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMCB, RNXT, DYAI, and AKTX Company DescriptionsAkari Therapeutics NASDAQ:AKTX$1.44 +0.07 (+5.11%) As of 03:59 PM EasternAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Dyadic International NASDAQ:DYAI$1.22 -0.01 (-0.81%) As of 04:00 PM EasternDyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.PharmaCyte Biotech NASDAQ:PMCB$1.24 0.00 (0.00%) As of 04:00 PM EasternPharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.RenovoRx NASDAQ:RNXT$0.96 -0.01 (-1.01%) As of 04:00 PM EasternRenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
